14.08
-0.09 (-0.64%)
| Previous Close | 14.17 |
| Open | 14.12 |
| Volume | 291,453 |
| Avg. Volume (3M) | 801,587 |
| Market Cap | 4,982,433,280 |
| Price / Earnings (Forward) | 21.88 |
| Price / Sales | 1.02 |
| Price / Book | 0.780 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Bausch + Lomb Corporation | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.25 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Icahn Carl C | 31 Mar 2025 | 3,500,000 |
| Goldentree Asset Management Lp | 30 Jun 2025 | 2,583,185 |
| Oaktree Capital Management Lp | 30 Jun 2025 | 2,521,245 |
| Maple Rock Capital Partners Inc. | 31 Mar 2025 | 1,971,053 |
| Whitebox Advisors Llc | 31 Mar 2025 | 1,622,876 |
| Nomura Holdings Inc | 31 Mar 2025 | 1,256,181 |
| Clearline Capital Lp | 31 Mar 2025 | 893,790 |
| Clark Estates Inc/Ny | 30 Jun 2025 | 850,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (HC Wainwright & Co., 13.64%) | Buy |
| 16.00 (Evercore ISI Group, 13.64%) | Buy | |
| 16.00 (Barclays, 13.64%) | Hold | |
| Median | 15.50 (10.09%) | |
| Low | 13.00 (Morgan Stanley, -7.67%) | Hold |
| Average | 15.17 (7.74%) | |
| Total | 2 Buy, 4 Hold | |
| Avg. Price @ Call | 13.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 01 Aug 2025 | 13.00 (-7.67%) | Hold | 13.50 |
| HC Wainwright & Co. | 31 Jul 2025 | 16.00 (13.64%) | Buy | 13.63 |
| Wells Fargo | 31 Jul 2025 | 15.00 (6.53%) | Hold | 13.63 |
| Citigroup | 09 Jul 2025 | 15.00 (6.53%) | Hold | 14.05 |
| Evercore ISI Group | 08 Jul 2025 | 16.00 (13.64%) | Buy | 14.00 |
| Barclays | 09 Jun 2025 | 16.00 (13.64%) | Hold | 11.98 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |